B-cell chronic lymphocytic leukemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:67038OMIM:109543C91.1
Who is this for?
Show terms as
13FDA treatments123Active trials248Specialists8Treatment centers8Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

B-cell chronic lymphocytic leukemia, often called CLL or B-CLL, is a type of blood cancer that starts in white blood cells called B-lymphocytes (or B-cells). These are cells that normally help your body fight infections. In CLL, abnormal B-cells grow out of control and build up in the blood, bone marrow, and lymph nodes. Unlike some cancers that grow very fast, CLL usually develops slowly over many years. It is the most common type of leukemia in adults in Western countries. Because CLL grows slowly, many people have no symptoms at first and are diagnosed through a routine blood test. Over time, the buildup of abnormal cells can crowd out healthy blood cells, leading to problems like fatigue, frequent infections, and swollen lymph nodes. The spleen and liver may also become enlarged. Treatment has improved greatly in recent years. Many people with early-stage CLL are simply monitored with regular check-ups, a strategy called 'watch and wait.' When treatment is needed, doctors now have powerful targeted drugs — such as ibrutinib, acalabrutinib, venetoclax, and obinutuzumab — that work much better than older chemotherapy. While CLL is generally not curable with standard treatments, many people live for decades with good quality of life. Stem cell transplant offers a potential cure for some patients.

Also known as:

Key symptoms:

Swollen lymph nodes in the neck, armpits, or groin (usually painless)Feeling very tired or weakFrequent or hard-to-treat infectionsNight sweatsUnintentional weight lossFever without a clear causeEnlarged spleen causing discomfort or fullness in the bellyEnlarged liverEasy bruising or bleedingPale skin due to low red blood cell counts (anemia)Shortness of breathFeeling full quickly when eating

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Jul 2026variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway

The Royal Wolverhampton Hospitals NHS Trust

TrialNOT YET RECRUITING
Jun 2026Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

University Hospital, Basel, Switzerland — PHASE1

TrialNOT YET RECRUITING
May 2026Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

SWOG Cancer Research Network — PHASE3

TrialNOT YET RECRUITING
Apr 2026Precision Physical Exercise for Personalized Onco-Hematology.

University of Salamanca — NA

TrialNOT YET RECRUITING
Mar 2026Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

National Heart, Lung, and Blood Institute (NHLBI) — EARLY_PHASE1

TrialRECRUITING
Mar 2026Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

Henan Cancer Hospital — PHASE2

TrialNOT YET RECRUITING
Feb 2026Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center — PHASE1

TrialRECRUITING
Jan 2026Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

AstraZeneca — PHASE2

TrialNOT YET RECRUITING
Dec 2025Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Paolo Caimi, MD — PHASE1

TrialNOT YET RECRUITING
Nov 2025Mosunetuzumab for CLL MRD Clearance

Inhye Ahn — PHASE1, PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

13 available

Campath

alemtuzumab· Genzyme Corporation■ Boxed Warning

CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)

CALQUENCE

acalabrutinib· Acerta Pharma, LLC (a member of the AstraZeneca Group)

For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

ARZERRA

ofatumumab· Novartis Pharmaceuticals Corporation■ Boxed Warning

for the treatment of patients with CLL refractory to fludarabine and alemtuzumab

COPIKTRA

duvelisib· Secura Bio, Inc.■ Boxed Warning

indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after at least two prior lines of systemic therapy

Fludara

Fludarabine phosphate· Berlex Laboratories, Inc.■ Boxed Warning
The treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent co

The treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.

Acetylcysteine

ACETYLCYSTEINE· Hospira, Inc.

adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in chronic emphysema

GAZYVA

obinutuzumab· Genentech Inc., a member of the Roche Group■ Boxed Warning

in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)

Bendeka

bendamustine for 50 ml admixture· Eagle Pharmaceuticals, Inc.
BENDEKA injection is an alkylating drug indicated for treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been esta

BENDEKA injection is an alkylating drug indicated for treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.

BRUKINSA

zanubrutinib· BeOne Medicines USA, Inc.

BRUKINSA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

VENCLEXTA

venetoclax· AbbVie, Inc

For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

IMBRUVICA

ibrutinib· Pharmacyclics, LLC

IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Rituxan

rituximab· Genentech, Inc.■ Boxed Warning

Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)

Treanda

Bendamustine hydrochloride· Cephalon, Inc.

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia

Clinical Trials

20 recruitingView all trials with filters →
Phase 32 trials
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Phase 3
Actively Recruiting
PI: Study Director (Dizal (Jiangsu) Pharmaceutical Co., Ltd.) · Sites: Nanjing, Jiangsu; Tianjin, Tianjin Municipality · Age: 1899 yrs
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
Phase 3
Active
PI: Jennifer A Woyach (Alliance for Clinical Trials in Oncology) · Sites: Birmingham, Alabama; Anchorage, Alaska +858 more · Age: 6599 yrs
Phase 42 trials
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Phase 4
Actively Recruiting
· Sites: Charlotte, North Carolina; Columbus, Ohio +21 more · Age: 18130 yrs
Vaccine Responses in Patients With B Cell Malignancies
Phase 4
Actively Recruiting
PI: Adrian U Wiestner, M.D. (National Heart, Lung, and Blood Institute (NHLBI)) · Sites: Bethesda, Maryland · Age: 1890 yrs
Other16 trials
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Actively Recruiting
PI: Joerg Herrmann, MD (Mayo Clinic in Rochester) · Sites: Rochester, Minnesota
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Actively Recruiting
PI: ABBVIE INC. (AbbVie) · Sites: Vitoria-Gasteiz, Alava; Manresa, Barcelona +23 more · Age: 1899 yrs
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Actively Recruiting
PI: ABBVIE INC. (AbbVie) · Sites: Sankt Pölten, Lower Austria; Graz, Styria +68 more · Age: 1899 yrs
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
Active
· Sites: Piteşti, Argeş; Oradea, Bihor County +17 more · Age: 18130 yrs
Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study
Actively Recruiting
PI: Fatih Demirkan, Prof (Dokuz Eylum Medical Faculty) · Sites: Izmir · Age: 1899 yrs
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Actively Recruiting
PI: Andres Chang, MD, PhD (Emory University) · Sites: Atlanta, Georgia; Atlanta, Georgia · Age: 1899 yrs
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Actively Recruiting
· Sites: Innsbruck, Tyrolia; Graz +3 more · Age: 1899 yrs
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Actively Recruiting
PI: Amrita Desai (OHSU Knight Cancer Institute) · Sites: Portland, Oregon · Age: 1899 yrs
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
Actively Recruiting
PI: Christopher Fletcher, MD (School of Medicine and Public Health, University o) · Sites: Madison, Wisconsin · Age: 1899 yrs
National Acalabrutinib Observational Study
Active
PI: Anne Quinquennel, Doctor (Hôpital Robert Debré, Reims, France) · Sites: Aix-en-Provence; Amiens +59 more · Age: 1899 yrs
The Pathogenesis and Prognostic Factors of Lymphoma
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality
Current Status of BTKi Treatment for CLL/SLL in China
Actively Recruiting
· Sites: Nanjin, Jiangsu · Age: 1880 yrs
Understanding Chronic Lymphocytic Leukemia
Actively Recruiting
PI: Jennifer Brown, MD,PhD (Dana-Farber Cancer Institute) · Sites: Boston, Massachusetts · Age: 1899 yrs
Watch and Wait or Worry and Wait in Indolent Lymphoma
Enrolling by Invitation
PI: Ja Min Byun, MD, PhD (Seoul National University Hospital) · Sites: Seoul, Gangnam-gu; Seoul, Guro-gu +2 more · Age: 1999 yrs
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Actively Recruiting
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Milwaukee, Wisconsin · Age: 1899 yrs
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Actively Recruiting
PI: Nirav Shah (Medical College of Wisconsin) · Sites: Milwaukee, Wisconsin · Age: 1880 yrs

Specialists

Showing 25 of 248View all specialists →
AD
Alexey Danilov
DUARTE, CA
Specialist
PI on 2 active trials
JY
Janna A Yoshimoto
Specialist
1 B-cell chronic lymphocytic leukemia publication
HT
Ho-Yang Tsai
Specialist
1 B-cell chronic lymphocytic leukemia publication
KC
Kaitlin M Curran
PHOENIX, AZ
Specialist
1 B-cell chronic lymphocytic leukemia publication
BE
Bayarmaa Enkhbayar
Specialist
1 B-cell chronic lymphocytic leukemia publication
SW
Shang-Ju Wu
Specialist
1 B-cell chronic lymphocytic leukemia publication
PA
Paul R Avery
MONROVIA, CA
Specialist
1 B-cell chronic lymphocytic leukemia publication
SL
Shao-Chia Lu
Specialist
1 B-cell chronic lymphocytic leukemia publication
ER
Emily D Rout
Specialist
1 B-cell chronic lymphocytic leukemia publication
VC
Vanessa Coyne
PAWTUCKET, RI
Specialist
1 B-cell chronic lymphocytic leukemia publication
JL
Julia D Labadie
Specialist
1 B-cell chronic lymphocytic leukemia publication
SL
Suh-Yuen Liang
Specialist
1 B-cell chronic lymphocytic leukemia publication
HM
Heather L Mead
BALTIMORE, MD
Specialist
1 B-cell chronic lymphocytic leukemia publication
AA
Anne C Avery
Specialist
1 B-cell chronic lymphocytic leukemia publication
TA
Takashi Angata
Specialist
1 B-cell chronic lymphocytic leukemia publication
AM
Adam J Olszewski, MD
New Haven, Connecticut
Specialist

Rare Disease Specialist

PI on 2 active trials1 B-cell chronic lymphocytic leukemia publication
TM
Timothy M. Kuzel, MD
HOUSTON, TX
Specialist
PI on 11 active trials
WM
Wyndham H Wilson, M.D.
BETHESDA, MD
Specialist
PI on 8 active trials

Treatment Centers

8 centers
⚗️ Trial Site

Washington University School of Medicine

📍 St Louis, Missouri

👤 Meagan A Jacoby, M.D., Ph.D.

👤 Janssen Research & Development, LLC Clinical Trial

⚗️ Trial Site

Mayo Clinic in Rochester

📍 Rochester, Minnesota

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Financial Resources

8 resources
Campath(alemtuzumab)Genzyme Corporation
CALQUENCE(acalabrutinib)Acerta Pharma, LLC (a member of the AstraZeneca Group)
ARZERRA(ofatumumab)Novartis Pharmaceuticals Corporation
COPIKTRA(duvelisib)Secura Bio, Inc.
GAZYVA(obinutuzumab)Genentech Inc., a member of the Roche Group
VENCLEXTA(venetoclax)AbbVie, Inc
Rituxan(rituximab)Genentech, Inc.
Treanda(Bendamustine hydrochloride)Cephalon, Inc.

Travel Grants

No travel grants are currently matched to B-cell chronic lymphocytic leukemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open B-cell chronic lymphocytic leukemiaForum →

No community posts yet. Be the first to share your experience with B-cell chronic lymphocytic leukemia.

Start the conversation →

Latest news about B-cell chronic lymphocytic leukemia

1 articles
Clinical trialUNITERAREApr 5, 2026
New Recruiting Trial: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, an
See all news about B-cell chronic lymphocytic leukemia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my CLL, and what do my chromosome and gene test results mean for my outlook?,Do I need to start treatment now, or is 'watch and wait' appropriate for me?,Which treatment would you recommend for me, and why — and what are the main side effects?,How will we know if the treatment is working, and what happens if it stops working?,Are there clinical trials I should consider?,What vaccines do I need, and are there any I should avoid?,Should my family members be tested or monitored for CLL?

Common questions about B-cell chronic lymphocytic leukemia

What is B-cell chronic lymphocytic leukemia?

B-cell chronic lymphocytic leukemia, often called CLL or B-CLL, is a type of blood cancer that starts in white blood cells called B-lymphocytes (or B-cells). These are cells that normally help your body fight infections. In CLL, abnormal B-cells grow out of control and build up in the blood, bone marrow, and lymph nodes. Unlike some cancers that grow very fast, CLL usually develops slowly over many years. It is the most common type of leukemia in adults in Western countries. Because CLL grows slowly, many people have no symptoms at first and are diagnosed through a routine blood test. Over ti

How is B-cell chronic lymphocytic leukemia inherited?

B-cell chronic lymphocytic leukemia follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does B-cell chronic lymphocytic leukemia typically begin?

Typical onset of B-cell chronic lymphocytic leukemia is adult. Age of onset can vary across affected individuals.

Are there clinical trials for B-cell chronic lymphocytic leukemia?

Yes — 20 recruiting clinical trials are currently listed for B-cell chronic lymphocytic leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat B-cell chronic lymphocytic leukemia?

25 specialists and care centers treating B-cell chronic lymphocytic leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for B-cell chronic lymphocytic leukemia?

8 patient support programs are currently tracked on UniteRare for B-cell chronic lymphocytic leukemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.